CA9 and cancer: Despite the great potential of CAIX for developing cancer-targeted therapies, the expression of this enzyme occurs in a few healthy tissues, such as intrahepatic biliary ducts [15], triggering hepatotoxicity in patients treated with anti-CAIX murine G250 CAR T cells in clinical trials [16,17].